NCCN
Updates Cancer- and Treatment-Related Anemia Guidelines
FORT
WASHINGTON, Pa.--(BUSINESS WIRE)--Dec 20, 2007 - The National
Comprehensive Cancer Network (NCCN) announces important updates to the
NCCN Cancer- and Treatment-Related Anemia Guidelines relating to the
use of erythropoietin-stimulating agents...
Marketing of
Viadur (leuprolide acetate implant) to Phase Out by April 2008
Other therapies
available for patients WAYNE, N.J., December 20, 2007 /PRNewswire/ --
Bayer HealthCare Pharmaceuticals Inc. announced today that after
careful consideration, the company will discontinue marketing of
Viadur(R) (leuprolide acetate...
Hemispherx
Biopharma Comments on 2005 BDO Audit News
PHILADELPHIA--(BUSINESS
WIRE)--Dec 20, 2007 - Hemispherx Biopharma, Inc. (AMEX:HEB) today
commented on recent news of the internal operating irregularities
within BDO Seidman ("BDO") and the resultant restatement of the
Hemispherx financial results...
Compugen and
Roche Sign Agreement to Identify Genetic Variations Predictive of Drug
Response in Rheumatoid Arthritis Patients
TEL AVIV,
Israel--(BUSINESS WIRE)--Dec 20, 2007 - Compugen Ltd. (NASDAQ:CGEN)
announced today that it has signed a collaborative discovery and
license agreement with Roche. The collaboration will cover the
identification and validation of genetic...
New Drug
Approvals
FDA Approves
New Mechanism of Action Labeling for Ranexa
PALO ALTO, Calif., December 18, 2007
/PRNewswire-FirstCall/ -- CV Therapeutics, Inc. announced today that
the U.S. Food and Drug Administration (FDA) has approved new language
for the product labeling for Ranexa (ranolazine extended-release...
Bystolic, a
Novel Beta Blocker, is Now Approved by the FDA for the Treatment of
Hypertension
NEW YORK, December
18, 2007 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. and Mylan
Inc. announced today that the novel beta blocker Bystolic (nebivolol)
was approved by the U.S. Food and Drug Administration (FDA) for the
treatment of...
Genzyme
Announces FDA Approval of Thyrogen for Use in Thyroid Cancer Ablation
CAMBRIDGE, Mass.,
December 17, 2007 /PRNewswire-FirstCall/ -- Genzyme Corp. announced
today that the U.S. Food and Drug Administration (FDA) has approved a
supplemental indication for Thyrogen (thyrotropin alfa for injection)
to be used...
